reviewed 06 Oct 2026

Psilocybin law is moving. This is the public record.

Every change is approved by a person before it publishes.

99 states and countries tracked · 333 clinical trials indexed · 191 sources cited · 231 changes logged in public

Is it legal where you are?

Under federal law, psilocybin is illegal in every US state, no exceptions. What your state adds on top is the part that varies, and two of them now license supervised sessions. Find yours on the map, or jump straight to its record.

Countries, A to Z

Traveling, or checking on home? Open your country below: the current status, the law behind it, and what changed last.

Legal 2 · Medical use 7 · Decriminalized 12 · Mixed 6 · Illegal 20 · the United States is tracked state by state above

Could you join a clinical trial?

The honest picture first: most registered trials are not taking new participants, and the board below shows exactly where each one stands. Starting from your condition narrows it fastest.

JurisdictionRecruitingActiveCompletedClosedTotal
All jurisdictions137609442333
Canada2187541
Maryland18719448
California17812340
New York1538026
Texas944017

And 51 more jurisdictions hold trials.

Statuses as reported by each study team; a multi-site trial counts in each hostOct 2026 review

Closed covers trials terminated, suspended, withdrawn or left unverified. Every row’s four figures add to its own total; a trial with sites in several jurisdictions counts in each, so the place totals do not add to the register’s.

See all 333trials →Which trials are recruiting →

What has the research found?

Six findings from the peer-reviewed literature, each linked to the paper itself, so you can read what the researchers actually reported. The rest live on the research page.

Anxiety2026
Eighteen participants sampled from a large randomised, open-label phase 2 trial of psilocybin-assisted therapy for generalised anxiety disorder gave 29 semi-structured interviews before and…

longitudinal qualitative interview study within a trial · Phase Phase 2 · n=18

Ham et al. · Psychology and psychotherapy

Population use2026
The 2023 International Cannabis Policy Study asked respondents in Canada, the United States, Australia and New Zealand about lifetime, past-year and past-month use of psilocybin, LSD

repeated cross-sectional survey across four countries

Graham et al. · The International journal on drug policy

OCD2026
Does it ease OCD?A first small controlled trial set psilocybin against an active sedative in people with obsessive-compulsive disorder.

RCT · Phase 1/2 · n=15

Moreno et al. · Journal of Psychopharmacology

Formulation2026
A randomized, within-subject crossover trial in 20 healthy adults…

randomized crossover trial · n=20

Tai et al. · Journal of psychopharmacology (Oxford, England)

Depression2026
Nine adults aged between eighteen and sixty-five who met criteria for both major depressive disorder and borderline personality disorder received a single dose of psilocybin in an…

open-label pilot study · n=9

Grant et al. · Clinical neuropharmacology

Attitudes2026
A thirty-question survey was mailed and sent by digital newsletter to registered psychiatrists in Louisiana, asking how strongly they agreed with statements about psilocybin research

mailed and emailed attitude survey · n=49

Husein et al. · Psychedelic medicine (New Rochelle, N.Y.)

All 164 studies →

What is moving?

Laws, rules, bills, research, trials: everything that changed lately, in one stream, each item linked to its record.

Every change, newest first →

Where is this heading?

The next change is already on paper somewhere: bills before legislatures, rules out for comment, trials still enrolling. None of it is a promise. All of it is here, dated.

Places with pending legislation
38
Trials in the recruiting stage
137
Legal2
Medical use7
Decriminalized12
Mixed6
Illegal20

Open the full register →

Track changes to psilocybin law.

One free email a month: what changed, and where. 231 changes logged in public, each one dated.

No spam. Never shared. Unsubscribe anytime. Privacy statement

The law won’t email you. We will.